Methazolamide (CAS 554-57-4) Suppliers and Product Information

Methazolamide is a carbonic anhydrase inhibitor used in the treatment of glaucoma. It reduces intraocular pressure and cerebrospinal fluid flow. The compound also shows potential in reducing electroshock-induced seizures and inhibiting the production of reactive oxygen species in certain cellular models.

Chemical Properties: Methazolamide is a white solid with a pKa of 7.30 at 25°C. It has a predicted density of 1.6625 g/cm³ and a refractive index of 1.6270.

Safety Information: Methazolamide is classified as harmful (Xn) with risk statements 20/21/22 and 40. Safety precautions include S22 and S36. It has a WGK (Water Hazard Class) of 3 in Germany.

Frequently Asked Questions about Methazolamide

Q: What is the primary use of Methazolamide?

A: Methazolamide is primarily used in the treatment of glaucoma. It acts as a carbonic anhydrase inhibitor to reduce intraocular pressure.

Q: How does Methazolamide work?

A: Methazolamide works by inhibiting the enzyme carbonic anhydrase, which leads to decreased production of aqueous humor in the eye, thereby reducing intraocular pressure.

Q: Are there any other potential applications for Methazolamide?

A: Besides its use in glaucoma treatment, research has shown potential applications in reducing electroshock-induced seizures and inhibiting the production of reactive oxygen species in certain cellular models. It may also have effects on reducing cerebral edema in some conditions.

Q: What are the typical dosage forms and administration routes for Methazolamide?

A: Methazolamide is typically administered orally. The usual dose for glaucoma treatment is 50 to 100 mg two to three times a day.

Q: How should Methazolamide be stored?

A: Methazolamide should be stored at 2-8°C. After reconstitution, it can be aliquoted and frozen at -20°C, where stock solutions remain stable for up to 3 months.